Darovasertib plus crizotinib: response, duration of response, and overall survival trend in the OptimUM-02 topline results
Darovasertib plus crizotinib: progressive disease as best response and discussant assessment against checkpoint inhibitor outcomes
Historical response, progression-free survival, and overall survival benchmarks cited by the sponsor
Historical 5-year survival in metastatic uveal melanoma
Tebentafusp: median overall survival in the primary analysis and 5-year survival in HLA-A∗02:01-positive disease
Expert expectation of real-world overall survival with tebentafusp-based treatment